| Item Type | Name |
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Antineoplastic Agents, Alkylating
|
|
Concept
|
Antineoplastic Agents, Phytogenic
|
|
Academic Article
|
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
|
|
Academic Article
|
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
|
|
Academic Article
|
Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.
|
|
Academic Article
|
Targeted molecules in small cell lung cancer.
|
|
Academic Article
|
Targeting c-Kit mutations: basic science to novel therapies.
|
|
Academic Article
|
Phase II study of imatinib in patients with small cell lung cancer.
|
|
Academic Article
|
Therapeutic targeting of the receptor tyrosine kinase Met.
|
|
Academic Article
|
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
|
|
Academic Article
|
Novel therapies in lung cancer.
|
|
Academic Article
|
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
|
|
Academic Article
|
c-Met inhibition.
|
|
Academic Article
|
A review of topoisomerase inhibition in lung cancer.
|
|
Academic Article
|
c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.
|
|
Academic Article
|
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
|
|
Academic Article
|
MET receptor tyrosine kinase.
|
|
Academic Article
|
The role of chemokine receptor CXCR4 in lung cancer.
|
|
Academic Article
|
Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers.
|
|
Academic Article
|
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
|
|
Academic Article
|
Non-receptor tyrosine kinase inhibitors in lung cancer.
|
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
|
Academic Article
|
A novel classification of lung cancer into molecular subtypes.
|
|
Academic Article
|
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
|
|
Academic Article
|
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
|
|
Academic Article
|
Therapeutic targeting of receptor tyrosine kinases in lung cancer.
|
|
Academic Article
|
Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer.
|
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
|
Academic Article
|
Review of clinic trials: agents targeting c-Met.
|
|
Academic Article
|
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
|
|
Academic Article
|
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
|
|
Academic Article
|
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
|
|
Academic Article
|
C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes.
|
|
Academic Article
|
The role of EGFR inhibition in the treatment of non-small cell lung cancer.
|
|
Academic Article
|
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
|
|
Academic Article
|
Role of MetMAb (OA-5D5) in c-MET active lung malignancies.
|
|
Academic Article
|
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
|
|
Academic Article
|
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
|
|
Academic Article
|
MET as a possible target for non-small-cell lung cancer.
|
|
Academic Article
|
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
|
|
Academic Article
|
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
|
|
Academic Article
|
Mitochondrial dynamics: biology and therapy in lung cancer.
|
|
Academic Article
|
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
|
|
Academic Article
|
Molecular pathways and therapeutic targets in lung cancer.
|
|
Academic Article
|
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
|
|
Academic Article
|
AXL mediates resistance to cetuximab therapy.
|
|
Academic Article
|
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
|
|
Academic Article
|
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
|
|
Academic Article
|
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
|
|
Academic Article
|
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
|
|
Academic Article
|
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
|
|
Academic Article
|
MET as a drug target.
|
|
Academic Article
|
Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
|
|
Academic Article
|
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
|
|
Academic Article
|
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
|
|
Academic Article
|
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
|
|
Academic Article
|
RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
|
|
Academic Article
|
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
|
|
Academic Article
|
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
|
|
Academic Article
|
Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
|
|
Academic Article
|
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
|
|
Academic Article
|
2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells.
|
|
Academic Article
|
EphB4: A promising target for upper aerodigestive malignancies.
|
|
Academic Article
|
2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76.
|
|
Academic Article
|
Managing Patients With Relapsed Small-Cell Lung Cancer.
|
|
Academic Article
|
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.
|
|
Academic Article
|
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
|
|
Academic Article
|
Targeted Therapies in Non-small-Cell Lung Cancer.
|
|
Academic Article
|
Notch signaling in breast cancer: From pathway analysis to therapy.
|
|
Academic Article
|
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
|
|
Academic Article
|
Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer.
|
|
Academic Article
|
Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines.
|
|
Academic Article
|
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
|
|
Academic Article
|
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors.
|
|
Academic Article
|
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
|
|
Academic Article
|
Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC).
|
|
Concept
|
Antineoplastic Agents, Immunological
|